Anagrelide, a novel platelet lowering option in essential thrombocythaemia: Treatment experience in 48 patients in Germany

European Journal of Haematology

Volumn 61, Issue 2, 1998, Pages 71-76

  Petrides, Petro E ^a,b   Beykirch, Maria K ^a   Trapp, Oliver M ^a  

^a Department of Medicine   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anagrelide; Essential thrombocythaemia; Hydroxyurea; Interferon ; Myeloproliferative disorders

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; HYDROXYUREA;

ABDOMINAL PAIN; ADULT; AGED; BLEEDING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; FEMALE; FLUID RETENTION; HEADACHE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0031830861     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1998.tb01064.x     Document Type: Review

References (17)

1. SPENCER CM, BRODGEN RN, Anagrelide. Drugs 1994: 47: 809-822
2. SILVERSTEIN MN, PETITT RM, SOLBERG LA, et al. Anagrelide: new drug for treating thrombocytosis. N Engl J Med 1988: 318: 1292-1294.
3. SILVERSTEIN MN, PETITT RM, SOLBERG LA, et al. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992: 92: 69-76.
4. SILVERSTEIN MN, PETRONE ME, PETITT RM, DEMENT MP, VUKOVICH RA. The safety profile of anagrelide for treatment of thrombocythaemia. Blood 1996: 88 (suppl 1): 583a.
5. TEFFERI A, SILVERSTEIN MN, PETITT RM, MESA RA, SOLBERG LA. Anagrelide as a new platelet-lowering agent in essential thrombocythaemia: mechanisms of action, efficacy, toxicity, current indications. Semin Thromb Hemost 1997: 23: 379-383.
6. BALDUINI CL, BERTOLINO G, NORIS P, ASCARI E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica 1992: 77: 40-43.
7. MAZZUCONI MG, DESANCTIS V, CHISTOLINI A. et al. Therapy with anagrelide in patients affected by essential thrombocythaemia: preliminary results. Hematologica 1992: 77: 315-317.
8. TRAPP OM, BEYKIRCH MK, PETRIDES PE. Anagrelide for treatment of patients with chronic myelogenous leukaemia and a high platelet count. Blood Cells Mol Dis 1998: 24: 9-13.
9. PETRIDES PE. Agrelin® (Anagrelide) is an efficacious platelet reducing drug in patients with primary thrombocythaemia. Blood 1994: 84: S635a.
10. PETRIDES PE. Treatment of essential thrombocythaemia with Agrelin®: The German experience. Br J Hematol 1996: 93 (suppl 2): 237.
11. CORTELAZZO S, VIERO P, FINAZZI G, D'EMILIO A, RODEGHIERO F, BARBUI T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythaemia. J Clin Oncol 1990: 8: 556-562.
12. FURGERSON JL, VUKELJA SJ, BAKER WJ, O'ROURKE TJ. Acute myeloid leukaemia evolving from essential thrombocythaemia in two patients treated with hydroxyurea. Am J Hematol 1996: 51: 137-140.
13. WEINFELD A, SWOLIN B, WESTIN J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders. Eur J Hematol 1994: 52: 134-139.
14. STERKERS Y, PREUDHOMME C, LAI JL, et al. Acute myeloid leukaemia and myelodysplastic syndromes following essential thrombocythaemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998: 91: 616-622.
15. VADHER BD, MACHIN SJ, PATTERSEN KG, et al. Life threatening thrombotic and hemorrhagic problems associated with silent myeloproliferative disorders. Br J Hematol 1993: 85: 213-216.
16. MCCUNE JS, LILES D, LINDLEY C. Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations. Pharmacotherapy 1997: 17: 822-826.
17. CORTELAZZO S, FINAZZI G, RUGGERI M, et al. Hydroxyurea for patients with essential thrombocythaemia and high risk of thrombosis. N Engl J Med 1995: 332: 1132-1136.